(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -21.09% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Macrogenics's revenue in 2026 is $149,500,000.On average, 8 Wall Street analysts forecast MGNX's revenue for 2026 to be $3,996,581,698, with the lowest MGNX revenue forecast at $685,131,923, and the highest MGNX revenue forecast at $7,781,141,124. On average, 6 Wall Street analysts forecast MGNX's revenue for 2027 to be $3,993,340,350, with the lowest MGNX revenue forecast at $1,868,541,608, and the highest MGNX revenue forecast at $5,992,679,871.
In 2028, MGNX is forecast to generate $4,882,422,954 in revenue, with the lowest revenue forecast at $3,737,083,216 and the highest revenue forecast at $6,048,100,561.